Allarity Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-11.2M | $-24.5M | $-11.9M | $-16.1M | $-26.6M | $-6.6M |
| Depreciation & Amortization | — | $9.0K | $37.0K | $60.0K | $106.0K | $46.0K |
| Depreciation | — | — | — | — | $12.0K | $21.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $482.0K | $71.0K | $-71.0K | $1.8M | $6.4M | $616.0K |
| Net Cash from Operating Activities | $-14.8M | $-17.4M | $-12.7M | $-16.8M | $-14.9M | $-7.3M |
| Investing Activities | ||||||
| Capital Expenditures | $8.0K | $298.0K | $0 | $18.0K | — | $3.0K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-8.0K | $-298.0K | $0 | $791.0K | $1.0M | $-3.0K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | $3.2M | $0 | — | — | — | — |
| Net Cash from Financing Activities | $10.6M | $36.8M | $11.0M | $-1.3M | $33.8M | $6.0M |
| Net Change in Cash | — | — | — | $-17.3M | $19.9M | $-1.2M |
| Free Cash Flow | $-14.8M | $-17.7M | $-12.7M | $-16.8M | — | $-7.3M |